Ulcerative Colitis (UC)SOTHISNCT02738125
Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions
An observational study of Ulcerative Colitis (UC), run by AbbVie at 80 sites in France.
Trial summary
This study assesses the long?term effectiveness of adalimumab in subjects starting a treatment for ulcerative colitis in real life conditions, namely to describe the time to loss of clinical benefit in a time to event approach. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Ulcerative Colitis (UC)
- How many people
- 265 participants
- Where
- 80 sitesFrance
- Study dates
- 29 Apr 2016to 15 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Subjects starting/ receiving Adalimumab for UC
Who may be able to join
- Suffering from ulcerative colitis
- Naïve from Adalimumab
- Starting a treatment with adalimumab
- Capable of and willing to grant authorization for use/disclosure of data collected
- Able to read, understand, and complete patients questionnaires
Who cannot join
- None
Trial locations and contacts
80 sites in 1 country.
80 sites in 1 country
France80 sites
Centre Medical Alexandre Dumas /Id# 165857
Amiens, 80090
Duplicate_Hopital Robert Ballanger /ID# 151382
Aulnay-sous-Bois, 93602
CH Henri Duffaut /ID# 151383
Avignon, Provence-Alpes-Côte d'Azur Region, 84902
CH Henri Duffaut /ID# 151499
Avignon, Provence-Alpes-Côte d'Azur Region, 84902
Cabinet Medical /ID# 155460
BAIE Mahault, Guadeloupe, 97122
Centre Hospitalier de la Cote /ID# 163714
Bayonne, Pyrenees-Atlantiques, 64100
Polyclinique du Tondu /ID# 161977
Bordeaux, 33082
Centre Endo Nord Isere /ID# 151390
Bourgoin, 38300
Geier, Cabinet Medical /ID# 149652
Brest, 29200
Hopital de la Cavale Blanche /ID# 152618
Brest, 29200
Hopital de la Cavale Blanche /ID# 153608
Brest, 29200
Cabinet Medical /ID# 151391
Caen, 14050
CHRU Tours - Hopital Trousseau /ID# 163503
Chambray-lès-Tours, 37170
Pole Sante Leonard de Vinci /ID# 151384
Chambray-lès-Tours, 37175
CH du Haut Anjou /ID# 151151
Château-Gontier, 53204
Ch Chauny /Id# 151149
Chauny, 02303
CHU Clermont-Ferrand /ID# 153527
Clermont, Auvergne-Rhône-Alpes, 63100
Hopital Beaujon /ID# 151498
Clichy, Île-de-France Region, 92110
Hopital Louis Mourier,Colombes /ID# 152650
Colombe, 92701
GHPSO CH Creil /ID# 151117
Creil, 60109
Centre Hosp Intercommunal de Creteil /ID# 152361
Créteil, Val-de-Marne, 94000
Cabinet Medical /ID# 150978
Douarnenez, 29100
Cabinet Medical /ID# 150845
Erstein, 67150
Centre Gastro Loire /ID# 151387
Gien, 45500
Clinique du Palais /ID# 151175
Grasse, 06130
CH La Rochelle - Hopital Saint Louis /ID# 151182
La Rochelle, 17019
CHU Grenoble - Hopital Michallon /ID# 151508
La Tronche, 38700
CHRU Lille - Hopital Claude Huriez /ID# 151514
Lille, Hauts-de-France, 59037
Duplicate_HOPITAL DUPUYTREN /ID# 157889
Limoges, 87042
CH Des Deux Vallees Longumeau /ID# 150977
Longjumeau, 91161
HCL - Hopital Edouard Herriot /ID# 151513
Lyon, 69003
Centre des consultations spécialisées de la sauvegarde /ID# 151515
Lyon, 69338
Hopital Saint Joseph /ID# 164405
Marseille, Bouches-du-Rhone, 13008
APHM - Hopital Nord /ID# 152620
Marseille, Bouches-du-Rhone, 13015
Centre Medical Les Sources /ID# 151174
Montigny-lès-Cormeilles, 95370
Chu de Nice-Hopital L'Archet Ii /Id# 151132
Nice, Alpes-Maritimes, 06200
Chu de Nice-Hopital L'Archet Ii /Id# 151181
Nice, Alpes-Maritimes, 06200
CHU NIMES - Hopital Caremeau /ID# 169178
Nîmes, Gard, 30029
AP-HP - Hopital Saint-Louis /ID# 151509
Paris, 75010
Hopital Paris Saint-Joseph /ID# 153526
Paris, 75014
AP-HP - Hopital Bichat - Claude-Bernard /ID# 151176
Paris, 75018
Cabinet Medical /ID# 151118
Paris, 75020
Cabinet Medical /ID# 152362
Paris, 75020
HCL - Hôpital Lyon Sud /ID# 151146
Pierre-Bénite, Auvergne-Rhône-Alpes, 69495
HCL - Hôpital Lyon Sud /ID# 151505
Pierre-Bénite, Auvergne-Rhône-Alpes, 69495
HCL - Hôpital Lyon Sud /ID# 165859
Pierre-Bénite, Auvergne-Rhône-Alpes, 69495
Duplicate_CHU LYON SUD /ID# 153801
Pierre-Bénite, 69495
Cabinet Medical /ID# 151092
Plérin, 22198
Cabinet Medical /ID# 151093
Plérin, 22198
Cabinet Medical /ID# 151094
Plérin, 22198
Cabinet Medical /ID# 151148
Poissy, 78300
Cabinet Medical /ID# 151555
Prades-le-Lez, 34730
CH Annecy Genevois Site Annecy /ID# 151131
Pringy, Haute-Savoie, 74374
CHRU Pontchaillou /ID# 166806
Rennes, 35033
CHU de SAINT ETIENNE - Hopital Nord /ID# 166807
Saint Priest EN Jarez, Pays de la Loire Region, 42270
CHU La Réunion - site St Denis - Félix-Guyon /ID# 151556
Saint-Denis, 97405
Centre de Consultations /ID# 151128
Saint-Nazaire, 44606
Centre de Consultations /ID# 151164
Saint-Nazaire, 44606
Centre de Consultations /ID# 155458
Saint-Nazaire, 44606
Cabinet Medical /ID# 151559
Saint-Quentin, 02100
CHU d'Amiens /ID# 152651
Salouël, 80480
Cabinet Medical /ID# 151558
Saverne, 67700
Cabinet Medical /ID# 151162
Strasbourg, 67000
Centre Medical du Clos de Pacy /ID# 151129
Sucy-en-Brie, 94370
Maison de Santé Protestante Bordeaux Bagatelle /ID# 151497
Talence, 33401
Cabinet Medical, Dr. Constant, /ID# 151119
Toulon, 83000
CHU Toulouse - Hopital Purpan /ID# 167179
Toulouse, Haute-Garonne, 31059
Clinique Pasteur /ID# 151088
Toulouse, 31076
Clinique Pasteur /ID# 155792
Toulouse, 31076
Clinique Ambroise Pare /ID# 161978
Toulouse, 31100
Cabinet Medical /ID# 170136
Toulouse, 31300
Cabinet Medical /ID# 152841
Toulouse, 31400
CHU Toulouse - Hopital Rangueil /ID# 157890
Toulouse, 31400
Duplicate_Hopital Trousseau /ID# 150168
Tours, 37044
Cabinet Medical /ID# 151557
Troyes, 10000
CHRU Nancy - Hôpitaux de Brabois /ID# 151147
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, 54500
GH Mutualiste Les Portes Du Sud /ID# 152374
Vénissieux, 69200
GH Mutualiste Les Portes Du Sud /ID# 159231
Vénissieux, 69200
Centre Hépato-Biliaire - Hopital Paul-Brousse /ID# 151152
Villejuif, 94800
Cabinet Medical /ID# 152617
Voiron, 38500
About this study
This study assesses the long?term effectiveness of adalimumab in subjects starting a treatment for ulcerative colitis in real life conditions, namely to describe the time to loss of clinical benefit in a time to event approach.
- Conditions
- Ulcerative Colitis (UC)
- Keywords
- Adalimumab, Ulcerative Colitis, SOTHIS, Effectiveness
- Medical subject headings
- Colitis, Ulcerative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Subjects starting/ receiving adalimumab | Subjects starting/ receiving Adalimumab for UC |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to loss of clinical benefit
Loss of clinical benefit will be defined as one of the following: loss of efficacy leading to adalimumab discontinuation or introduction/reinforcement of aminosalicylates, 6-mercaptopurine, or azathioprine, introduction or reinforcement of corticosteroids (any route), UC-related surgery, discontinuation of adalimumab due to adverse event, death.
Measured: Up to Month 120
Secondary outcomes (3)
Change from Baseline (Month 0) in Steroid-free remission
Steroid- free remission is defined as partial Mayo score <= 2 with no subscore >1 and no daily intake of prednisone.
Measured: From Month 0 to Month 120
Change from Baseline (Month 0) in Clinical Remission
Clinical remission is defined as partial Mayo score <= 2 with no subscore >1
Measured: From Month 0 to Month 120
Change from Baseline (Month 0) in Clinical Response
Clinical response is decrease in partial Mayo score >= 3 points and >= 30% from baseline plus a decrease in rectal bleeding subscore >= 1 or an absolute rectal bleeding subscore <= 1.
Measured: From Month 0 to Month 120
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2016 (estimated)
- Study start29 Apr 2016
- Primary completion15 Dec 2023
- Study completion15 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ulcerative Colitis (UC)Studies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 265 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02738125
- Sponsor's protocol ID
- P15-681
- Acronym
- SOTHIS
- Status last verified
- Dec 2024
- First submitted
- 11 Apr 2016
- Last updated
- 31 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 31 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions
- ClinicalTrials.gov ID
- NCT02738125
- Acronym / sponsor ID
- SOTHIS / P15-681
- Conditions
- Ulcerative Colitis (UC)
- Keywords
- Adalimumab, Ulcerative Colitis, SOTHIS, Effectiveness
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 265 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 29 Apr 2016 (actual)
- Primary completion
- 15 Dec 2023 (actual)
- Study completion
- 15 Dec 2023 (actual)
- First posted
- 14 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study assesses the long?term effectiveness of adalimumab in subjects starting a treatment for ulcerative colitis in real life conditions, namely to describe the time to loss of clinical benefit in a time to event approach.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Subjects starting/ receiving adalimumab | – | –Subjects starting/ receiving Adalimumab for UC |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects starting/ receiving Adalimumab for UC
Key inclusion criteria (5 listed)
- Suffering from ulcerative colitis
- Naïve from Adalimumab
- Starting a treatment with adalimumab
- Capable of and willing to grant authorization for use/disclosure of data collected
- Able to read, understand, and complete patients questionnaires
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Time to loss of clinical benefit
Time frame: Up to Month 120
Loss of clinical benefit will be defined as one of the following: loss of efficacy leading to adalimumab discontinuation or introduction/reinforcement of aminosalicylates, 6-mercaptopurine, or azathioprine, introduction or reinforcement of corticosteroids (any route), UC-related surgery, discontinuation of adalimumab due to adverse event, death.
3 secondary outcomes
Change from Baseline (Month 0) in Steroid-free remission
Time frame: From Month 0 to Month 120
Change from Baseline (Month 0) in Clinical Remission
Time frame: From Month 0 to Month 120
Change from Baseline (Month 0) in Clinical Response
Time frame: From Month 0 to Month 120
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Dec 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Ulcerative Colitis (UC)
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
Not yet recruitingObservational study
Non-Invasive Biomarker Monitoring in UC on Biologics
Ulcerative Colitis
RecruitingPhase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
RecruitingPhase 1/2
Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
RecruitingPhase 1/2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Ulcerative Colitis (UC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ABBVIE INC. study director
AbbVie
80 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ulcerative Colitis (UC), run by AbbVie at 80 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 80 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to loss of clinical benefit (time frame: Up to Month 120). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Dec 2024.